COVID-19 Update: Ziphuis Announces Promising Preclinical Data.
June 15, 2020
Ziphius Vaccines NV, Belgium, announced that they have obtained very promising preclinical results in mice concerning their COVID-19 vaccine candidate 'ZIP-1642'. If everything goes as planned, The Company is expected to take its vaccine candidate to the clinic by this year. In parallel, The Company is preparing for large-scale manufacturing of its vaccine. "We are currently in the process of building important global partnerships to increase our manufacturing capabilities. Once our vaccine is ready to go to the market, it is our goal to deliver at least 100 million doses of ZIP-1642 to contribute in the fight against this global pandemic."
ZIP-1642 consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens, such as a form of the Spike (S) protein, which is an essential protein for host cell infection and has been evaluated as a vaccine antigen for multiple other corona viruses. The vaccine consists of an mRNA-based technology, the platform has previously been used for the development of another vaccine. COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no approved vaccine for COVID-19.
About Ziphius Vaccines
Ziphius Vaccines NV is a pre-clinical gene technology company that focuses on messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. Together with Ghent University, Ziphius Vaccines is developing a portfolio of mRNA vaccines and therapeutics. To date, the Company has several therapeutic candidates in development in the fields of respiratory and endocrinological diseases, in addition to several prophylactic vaccines, including ZIP1642.
Headquartered in Oostkamp, Belgium, Ziphius Vaccines currently has strategic partnerships with experienced executives in the pharmaceutical industry that bring over 100 years of combined experience in drug development.